Immunovant (IMVT)
(Delayed Data from NSDQ)
$30.16 USD
+0.37 (1.24%)
Updated Aug 14, 2024 04:00 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Brokerage Reports
Immunovant, Inc. [IMVT]
Reports for Purchase
Showing records 101 - 106 ( 106 total )
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Pharmaceuticals/Specialty - Expert Call: An Update on the Tepezza Launch
Provider: Jefferies & Company
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
No Power, No Problem, as IMVT-1401 Hits Stat Sig in MG Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
First Quarter Financial Update for Immunovant; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
SC Formulation Should Secure a Place in the Blockbuster FcRn Space; Initiate With Buy and $34 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
KOL Perspectives on FcRn''s for the Treatment of Myasthenia Gravis
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D